Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Department of Nursing, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
BMJ Open. 2022 Feb 15;12(2):e056068. doi: 10.1136/bmjopen-2021-056068.
Enhanced recovery after surgery (ERAS) has been widely used in the perioperative period of lung cancer surgery. However, there remains a lack of comprehensive and systematic evidence on the effectiveness and safety of ERAS. This study aims to evaluate the efficacy and safety of ERAS in patients with lung cancer.
Eight databases (PubMed, Web of Science, Embase, Cochrane Library, CNKI, CBM, VIP and WANFANG) will be searched from inception to November 2021. Two reviewers will independently screen studies, extract data of interest and assess the risk of bias. The revised risk of bias tool 2 will be used to assess the risk of bias in randomised controlled trials. We will use the Grading of Recommendations, Assessment, Development and Evaluations to assess the certainty of evidence. We will carry out a random-effect meta-analysis focusing on the efficacy and safety variables. All analyses will be conducted using RevMan V.5.3.
Since the study will be a systematic review and will not involve direct contact with patients or make alterations to patient care, ethical approval and informed consent are not required for this study. The results of this review will be published in a peer-reviewed journal.
CRD42021250761.
加速康复外科（ERAS）已广泛应用于肺癌手术的围手术期。然而，关于 ERAS 的有效性和安全性仍缺乏全面和系统的证据。本研究旨在评估 ERAS 在肺癌患者中的疗效和安全性。
从建库至 2021 年 11 月，我们将检索 8 个数据库（PubMed、Web of Science、Embase、Cochrane Library、CNKI、CBM、VIP 和 WANFANG）。两位评审员将独立筛选研究、提取感兴趣的数据并评估偏倚风险。修订后的偏倚风险工具 2 将用于评估随机对照试验的偏倚风险。我们将使用推荐、评估、制定和评估分级法来评估证据的确定性。我们将进行一项随机效应荟萃分析，重点关注疗效和安全性变量。所有分析均将使用 RevMan V.5.3 进行。
由于本研究将是一项系统评价，且不会直接接触患者或改变患者的护理，因此本研究不需要伦理批准和知情同意。本综述的结果将发表在同行评议的期刊上。
PROSPERO 注册号：CRD42021250761。
